Cure My Disease

Don't miss your cure!

 Log in / Sign up

Experimental combo for tough leukemia shows promise in early trial

NCT ID NCT05780879

Terminated Disease control Sponsor: University of Michigan Rogel Cancer Center Source: ClinicalTrials.gov ↗

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This pilot study tested adding the targeted drug venetoclax to standard chemotherapy (FLAG or CLAG) for people with newly diagnosed secondary acute myeloid leukemia (sAML), a challenging blood cancer. The goal was to see if the combination could improve complete remission rates. Only 10 participants were enrolled before the study was terminated, so the results are very preliminary and not enough to draw firm conclusions.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance
Venetoclax (a targeted drug) combined with standard chemotherapy (FLAG or CLAG)
What this could lead to
If successful, this combination could improve remission rates for people with secondary acute myeloid leukemia, a hard-to-treat blood cancer.
What could go wrong
This was a very small pilot study (only 10 participants) that was terminated early, so results are limited and may not apply broadly. The combination also carries risks of serious side effects from chemotherapy.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for SECONDARY ACUTE MYELOID LEUKEMIA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

therapy related acute myeloid leukemia and myelodysplastic syndrome

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

SECONDARY ACUTE MYELOID LEUKEMIA

Contacts and locations

Locations

  • University of Michigan Rogel Cancer Center

    Ann Arbor, Michigan, 48109, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.